Record Quarter for ReWalk Medicare Placements
Revenue for Q2 2025 was $5.7 million, reflecting a record quarter for ReWalk Medicare placements.
Transition to In-House Manufacturing
Completed the transition to in-house manufacturing of the ReWalk Personal Exoskeleton, delivering cost savings, improved quality control, and greater production flexibility.
Growth in Active Pipeline
The active pipeline in the U.S. grew by 86% since Q3 2024, with more than 130 qualified leads in process.
Operational Efficiencies
Improved quarterly cash burn to $3.9 million, down from $5.6 million in Q2 2024, driven by operational efficiencies and facility consolidations.
International Success in Germany
The GmbH team in Germany is operating profitably, building a strong patient community, and using their payer acceleration and market scale to move quickly in rolling out innovative new business models.